ClinicalTrials.gg
CompletedNCT00930618NOCETERUpdated Dec 1, 2025

Reduction of Cesareans by Nitric Oxide (NO) Donors in Post Term Pregnancies

A Phase 3 interventional study of IMN and Placebo in Prolonged Pregnancy and Nulliparity, sponsored by Assistance Publique - Hôpitaux de Paris. Completed at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-01.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,409
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The purpose of this trial is to determine whether cervical ripening with isosorbide mononitrate reduce caesarean section in women with post term pregnancies.

Read the detailed description

The purpose of this trial is to determine whether cervical ripening with 40 mg of isosorbide mononitrate given intravaginally at 41+0, 41+2 and 41+4 weeks reduce cesarean section in nullipara with post term pregnancies. Treatments will be administered by midwifes in the maternity wards, women will be allowed to go back home in case of Bishop score\<6. Otherwise labor will be induced with oxytocin. If undelivered at 41+5, women with Bishop score\<6 will be induced with prostaglandins according to local protocols.

02

Conditions studied

  • Prolonged Pregnancy
  • Nulliparity

Browse trials for

Keywords

  • Prolonged pregnancy
  • Nulliparity
  • Cervical ripening
  • Induced labor
  • Cesarean section
03

In context

Pregnancy, Prolonged

30 studies on the registry are indexed under Pregnancy, Prolonged; 3 are open to participants now.

This study's enrollment of 1,409 is above the median of 128 across 24 interventional studies indexed under Pregnancy, Prolonged.

Browse Pregnancy, Prolonged studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > or = 18 years old
  • TAS > or = 95 mmHg
  • Singleton
  • Nulliparity
  • Term > or = 41 weeks + 0 day
  • Bishop score \< or = 5
  • Vertex presentation
  • Intact membranes
  • No of the study treatment
  • No maternal or fetal diseases which could indicate immediate labor induction
  • Written

Exclusion criteria

Exclusion criteria :

  • Multiple pregnancy
  • Multiparity
  • Term \< 41 weeks
  • Bishop score > 5
  • Breech presentation
  • Rupture of the membranes
  • Previous cesarean
  • Indication to immediate labor induction
  • to isosorbide mononitrate
  • No co-administration of antihypertensive drugs
  • No social security
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,409 participants (actual)

Study arms

  • Experimental
    IMN

    Isosorbide mononitrate

    Drug: IMN

  • Placebo comparator
    Placebo

    Administration of placebo of IMN

    Drug: Placebo

Interventions

  • DrugIMN

    Administration of 2 x 20 mg of isosorbide mononitrate at each administration with a maximum of three administrations

  • DrugPlacebo

    Administration of 2 X 20 mg of placebo of IMN at each administration with a maximum of three administration

06

What researchers measure

Primary outcomes

  1. Number of cesarean sections

    Time frame: 10 days

Secondary outcomes

  1. Number of labor inductions

    Time frame: 10 days

  2. Number of spontaneous labors

    Time frame: 10 days

  3. Cesarean for failed labor induction

    Time frame: 10 days

  4. Cesarean for FHR abnormalities

    Time frame: 10 days

  5. Cesarean for arrested labor

    Time frame: 10 days

  6. Mean time between randomisation and spontaneous labor

    Time frame: 10 days

  7. Isosorbide mononitrate adverse effects

    Time frame: 10 days

  8. Maternal satisfaction

    Time frame: 10 days

  9. Neonatal morbidity

    Time frame: 10 days

  10. Mean time between randomisation and delivery

    Time frame: 10 days

  11. Mean duration of labor

    Time frame: 10 days

07

Study locations

1 site
  • Robert Debré Hospital
    Paris, 75019, France
08

References and documents

Publications

  • Schmitz T, Fuchs F, Closset E, Rozenberg P, Winer N, Perrotin F, Verspyck E, Azria E, Carbonne B, Lepercq J, Maillard F, Goffinet F; Groupe de Recherche en Obstetrique et Gynecologie (GROG). Outpatient cervical ripening by nitric oxide donors for prolonged pregnancy: a randomized controlled trial. Obstet Gynecol. 2014 Dec;124(6):1089-1097. doi: 10.1097/AOG.0000000000000544. PubMed 25415159 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2009, a primary completion of Dec 2013 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2009
First posted
Jun 30, 2009
Start
Jun 2009
Primary completionActual
Dec 2013
CompletionActual
Apr 2014
Last update
Dec 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00930618
Collaborators
URC-CIC Paris Descartes Necker Cochin
Responsible party
Sponsor
First posted
Jun 30, 2009
Start date
Jun 2009
Primary completion
Dec 2013
Completion
Apr 2014
Last update
Dec 1, 2025

Study contacts

François Goffinet, MD, PhD
study director · Scientific Responsible

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion